Omeros Corporation
$ 13.25
0.76%
07 Aug - close price
- Market Cap 958,973,000 USD
- Current Price $ 13.25
- High / Low $ 13.44 / 12.92
- Stock P/E 11.52
- Book Value -0.88
- EPS 1.15
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -5.76 %
- 52 Week High 17.65
- 52 Week Low 3.89
About
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
Analyst Target Price
$33.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-31 | 2025-11-13 | 2025-08-14 | 2025-05-15 | 2025-03-31 | 2024-11-13 | 2024-08-07 | 2024-04-01 | 2024-03-26 | 2023-11-09 | 2023-08-09 |
| Reported EPS | 0.57 | -0.5464 | -0.32 | -0.53 | -0.65 | -0.55 | -0.64 | -1.12 | -0.75 | -0.15 | -0.82 | -0.7 |
| Estimated EPS | -0.39 | -0.5202 | -0.48 | -0.55 | -0.58 | -0.71 | -0.77 | -1.01 | -0.63 | -0.55 | -0.66 | -0.53 |
| Surprise | 0.96 | -0.0262 | 0.16 | 0.02 | -0.07 | 0.16 | 0.13 | -0.11 | -0.12 | 0.4 | -0.16 | -0.17 |
| Surprise Percentage | 246.1538% | -5.0365% | 33.3333% | 3.6364% | -12.069% | 22.5352% | 16.8831% | -10.8911% | -19.0476% | 72.7273% | -24.2424% | -32.0755% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.27 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OMER
2026-08-07 19:40:57
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Omeros Corporation (NASDAQ: OMER) after its stock price fell significantly. This follows the European Medicines Agency's negative opinion on Omeros's marketing authorization application for narsoplimab, a drug intended to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy. The firm encourages investors who purchased Omeros securities to contact them for more information regarding the investigation.
2026-08-07 09:40:57
This article provides a detailed liquidity mapping and trading strategy analysis for Omeros Corporation (NASDAQ: OMER) based on AI models. It highlights strong sentiment supporting an overweight bias, outlines specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry/target/stop loss levels, and presents a multi-timeframe signal analysis indicating strong support across all horizons.
2026-08-06 19:40:57
Omeros (NASDAQ:OMER) is scheduled to release its Q2 2026 earnings after market close on Thursday, August 13th. Analysts anticipate a loss of $0.27 per share and revenues of $12.7 million. The company's stock, which recently traded near $12.65, currently holds a "Moderate Buy" consensus rating with an average price target of $38.
2026-08-05 19:40:57
Omeros (NASDAQ:OMER) shares recently surpassed their two-hundred-day moving average, closing at $12.94 after reaching $13.05. The biopharmaceutical company reported better-than-expected quarterly earnings, with a loss of $0.24 per share against a projected $0.40 loss, and revenue of $9.89 million against a $4.19 million estimate. Analyst sentiment is mixed, holding a "Moderate Buy" consensus rating with a $38.00 target price, while insider transactions show a director recently sold a portion of their shares.
2026-08-03 15:40:06
Omeros Corporation announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for its drug YARTEMLEA®. This status allows eligible hospitals to receive up to $287,079 in additional Medicare reimbursement per patient for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) with YARTEMLEA, effective October 1, 2026. The decision aims to reduce the financial burden on hospitals and ensure timely patient access to the FDA-approved treatment.
2026-08-03 12:42:37
Omeros Corporation announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for YARTEMLEA® (narsoplimab-wuug), effective October 1, 2026. This status provides additional Medicare reimbursement to hospitals for treating eligible Medicare patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). YARTEMLEA is the only FDA-approved treatment for TA-TMA, a rare and life-threatening complication, and the NTAP status is expected to facilitate greater patient access by reducing the financial burden on hospitals.
